CoChat

Melanoma Lesions Independently Acquire T-cell Resistance during Metastatic Latency

Zhao, Fang, Sucker, Antje, Horn, Susanne, Heeke, Christina, Bielefeld, Nicola, Schrörs, Barbara, Bicker, Anne, Lindemann, Monika, Roesch, Alexander, Gaudernack, Gustav, Stiller, Mathias, Becker, Jürgen C., Lennerz, Volker, Wölfel, Thomas, Schadendorf, Dirk, Griewank, Klaus, Paschen, Annette · 2016 · Cancer Research
Cited by 73

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

Melanoma often recurs after a latency period of several years, presenting a T cell–edited phenotype that reflects a role for CD8+ T cells in maintaining metastatic latency. Here, we report an investigation of a patient with multiple recurrent lesions, where poorly immunogenic melanoma phenotypes were found to evolve in the presence of autologous tumor antigen–specific CD8+ T cells. Melanoma cells from two of three late recurrent metastases, developing within a 6-year latency period, lacked HLA class I expression. CD8+ T cell–resistant, HLA class I–negative tumor cells became clinically apparent 1.5 and 6 years into stage IV disease. Genome profiling by SNP arrays revealed that HLA class I loss in both metastases originated from a shared chromosome 15q alteration and independently acquired focal B2M gene deletions. A third HLA class I haplotype-deficient lesion developed in year 3 of stage IV disease that acquired resistance toward dominant CD8+ T-cell clonotypes targeting stage III tumor cells. At an early stage, melanoma cells showed a dedifferentiated c-Junhigh/MITFlow phenotype, possibly associated with immunosuppression, which contrasted with a c-Junlow/MITFhigh phenotype of T cell–edited tumor cells derived from late metastases. In summary, our work shows how tumor recurrences after long-term latency evolve toward T-cell resistance by independent genetic events, as a means for immune escape and immunotherapeutic resistance. Cancer Res; 76(15); 4347–58. ©2016 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-16-0008

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 73

Metadata

Authors
Zhao, F., Sucker, A., Horn, S., Heeke, C., Bielefeld, N., Schrörs, B., Bicker, A., Lindemann, M., Roesch, A., Gaudernack, G., Stiller, M., Becker, J. C., Lennerz, V., Wölfel, T., Schadendorf, D., Griewank, K., & Paschen, A.
Venue
Cancer Research
Published
2016-07-31
Volume
76
Issue
15
Pages
4347-4358
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2409135403
Cited by
73
References
11
FWCI
4.02
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Melanoma Lesions Independently Acquire T-cell Resistance during Metastatic Latency. https://app.cochat.ai/papers/10.1158/0008-5472.can-16-0008
The paper
Zhao, F., Sucker, A., Horn, S., Heeke, C., Bielefeld, N., Schrörs, B., Bicker, A., Lindemann, M., Roesch, A., Gaudernack, G., Stiller, M., Becker, J. C., Lennerz, V., Wölfel, T., Schadendorf, D., Griewank, K., & Paschen, A. (2016). Melanoma Lesions Independently Acquire T-cell Resistance during Metastatic Latency. Cancer Research. https://doi.org/10.1158/0008-5472.can-16-0008

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.